Centessa Pharmaceuticals plc

NASDAQ:CNTA

Biotechnology

Healthcare
$40.50 -0.19%

-$0.07 today

Market cap
$6.27B
Beta
1.12
P/E (TTM)
-24.4
EPS (TTM)
-$1.63
52W Low $12.30High $40.26

Volume 0.00M

Average 2.63M

CNTA Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Centessa Pharmaceuticals plcNASDAQ: CNTA

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin not reported for Q1 FY2026

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
—— QoQ
Last fiscal yearDec 2025
100.0%— YoY
LTMMar 2026
—— YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3 years———
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
100.0%
Year-over-year change
—

Gross Margin vs competitors

How CNTA compares with its peers on the latest reported figures

  • CNTA's FY2025 gross margin of 100.0% is the highest of the 7 companies compared; the peer median is 61.5%.
CNTA Competitors Peer median
Gross Margin for CNTA and competitors
Company Period LTM level YoY 3-year change
CNTACentessa Pharmaceuticals plcFY2025100.0% ——
RAREUltragenyx Pharmaceutical Inc.LTM Mar 202683.6% -1.6 pp-8.4 pp
AAPGAscentage Pharma Group InternationalFY202576.4% -20.6 pp-13.1 pp
XENEXenon Pharmaceuticals Inc.FY202566.1% —-33.9 pp
LEGNLegend Biotech CorporationLTM Sep 202657.0% -3.6 pp+16.2 pp
ZLABZai Lab LimitedLTM Jun 202656.5% -5.9 pp-7.1 pp
CGONCG Oncology, Inc. Common stockLTM Sep 2026-102.2% +3807.7 pp-107.2 pp
APGEApogee Therapeutics, Inc.FY2025— ——
CELCCelcuity Inc.FY2025— ——
DYNDyne Therapeutics, Inc.FY2025— ——
Peer median (excluding CNTA) 61.5%-3.6 pp-10.7 pp

Competitors are the stored peer set for CNTA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue006.85M015M
Cost of Revenue00000
Gross Profit006.85M015M
Gross Margin——100.0%—100.0%
Research & Development96.32M155.08M124.41M150.24M172.22M
Selling, General & Admin43.01M55.2M53.73M50.81M50.47M
Operating Expenses374.87M212.26M178.14M201.06M222.69M
Depreciation & Amortization34K131K810K942K921K
EBITDA(139.3M)(209.55M)(165.43M)(221.88M)(183.33M)
EBITDA Margin——-2413.9%—-1222.2%
Operating Income(374.87M)(212.26M)(171.28M)(201.06M)(207.69M)
Operating Margin——-2499.4%—-1384.6%
Interest Income0244K10.48M14.02M20.53M
Interest Expense2.55M7.28M9.91M10.09M11.46M
Other Income / Expenses(6.92M)(4.69M)(4.86M)(31.86M)11.98M
Income Before Tax(381.79M)(216.95M)(176.14M)(232.91M)(195.71M)
Pre-Tax Margin——-2570.3%—-1304.8%
Income Tax Expense114K(747K)(25.06M)2.84M1.82M
Net Income(381.9M)(216.21M)(151.09M)(235.76M)(197.53M)
Net Margin——-2204.7%—-1316.9%
EPS (Basic)(4.24)(2.31)(1.57)(2.06)(1.46)
EPS (Diluted)(4.24)(2.31)(1.57)(2.06)(1.46)
Weighted Avg Shares89.99M93.4M96.18M114.47M135.72M
Weighted Avg Shares (Diluted)89.99M93.4M96.18M114.47M135.72M

Centessa Pharmaceuticals plc

NASDAQ:CNTA

Intrinsic Alpha fair value

Locked

Current Price

$40.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.